Liquid Prami 60mL 1mg/mL

Pramipexole (Prami) is a dopamine agonist with inhibiting effects on prolactin release from the pituitary. This has allowed research into and shown positive effects with; Depression, Bipolar disorder, Gyno (Gynecomastia), Fibromyalgia, Cluster headaches, Sexual dysfunction, Parkinson's disease, Restless legs syndrome and the lowering of prolactin levels. Prami has shown very promising in treating many conditions from mental to hormonal and even physical, it truly is a great compound with many possibilities. It has shown extremely effective at lowering prolactin levels in various studies. This is of great interest because abnormally high levels of prolactin can cause unwanted effects, mainly an issue found in males with abnormal hormone levels. This may include symptoms such as lactation and Gyno (development of female like breast tissue). Prami would be ideal for research into treating these conditions, but also many more which may be caused by anti-depressant medication, anti-psychotic medication and from hormonal supplementation side effects (e.g. Gyno). Prami has also shown to be effective and well tolerated by test subjects. Prami has the half-life of about 8-9 hours. We are proud to offer you the highest quality Prami for all your research needs. Ref: 1) Comparison of Pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers.Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. http://www.ncbi.nlm.nih.gov/pubmed/16401653 2) Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.Schilling JC, Adamus WS, Palluk R. http://www.ncbi.nlm.nih.gov/pubmed/1350237 3) Decrease of prolactin secretion via stimulation of pituitary dopamine D-2 receptors after application of talipexole and SND 919.Domae M, Yamada K, Hanabusa Y, Matsumoto S, Furukawa T. http://www.ncbi.nlm.nih.gov/pubmed/2142088 4) New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.Harada T, Ishizaki F, Horie N, Nitta Y, Yamada T, Sasaki T, Nagakane T, Yasumatsu Y, Nitta K, Katsuoka H. http://www.ncbi.nlm.nih.gov/pubmed/22389951 5) Pramipexole Upregulates Dopamine Receptor D(2) and D(3) Expression in Rat Striatum.Tokunaga N, Choudhury ME, Nishikawa N, Nagai M, Tujii T, Iwaki H, Kaneta M, Nomoto M. http://www.ncbi.nlm.nih.gov/pubmed/22986363 6) The effect of pramipexole therapy on balance disorder and fall risk in Parkinson's disease at early stage: clinical and posturographic assessment.Güler S, Bir LS, Akdag B, Ardic F. http://www.ncbi.nlm.nih.gov/pubmed/22919514 7) The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial.Hori H, Kunugi H. http://www.ncbi.nlm.nih.gov/pubmed/22919308